It is now over one hundred years since von Behring and Kitsato
first concluded experiments that led to the use of passive
immunisation, employing antibodies raised in animals against
tetanus and diphtheria toxins. The advancement of technology both
in manufacturing purity product in a cost effective way and the
clinical research has proved that antibodies are one ofthe most
successful products in biotechnology. Monoclonal antibodies account
for between one-third and one-halfof all pharmaceutical products in
development and human clinical trials. Both the nature of
monoclonal antibody therapies and the relatively large size of the
monoclonal antibody dictate the production requirements, for many
ofthese therapeutics the monoclonal antibody product will be 100
kilogrammes or more per year. It is widely acknowledged that there
is currently a worldwide shortage of biomanufacturing capacity, and
the active pharmaceutical ingredient material requirements for
these products are expected to increase. Thus the industry is
looking for new sources and extensive studies are being carried out
not only for alternative technology to meet the needs but also to
reveal the new therapeutic applicationsofantibodies. This book
brings to the forefront current advances in novel technologies for
the manufacturing of monoclonal antibodies and also their extensive
clinical importance. The first four chapters give an overview of
the new technologies and the successful application in the
manufacture of monoclonal antibodies with clinical purity. The next
chapters address the application of antibodies in cancer therapy
and functional genomic therapy.
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!
Welcome to Loot.co.za!
Sign in / Register |Wishlists & Gift Vouchers |Help | Advanced search
